The United Kingdom and the United States have hammered out a landmark bilateral deal that will keep no import taxes on British medicine products being sold in the American market.
Agreement Details of the Deal
In exchange for the tariff guarantee, the UK has agreed to raise spending on drugs through the public health system. This pledge ensures that import taxes on these crucial products will be held at nothing for a duration of 36 months.
This development comes after earlier statements to significantly raise import taxes on branded drug products, with increases floated up to one hundred percent.
"This agreement between the UK reinforces the international landscape for new treatments and brings much-needed balance to American-British drug exports," a release said.
Trade Significance
Pharmaceuticals constitute one of the Britain's largest export categories to the America, which is easily the biggest market for leading UK drugmakers.
Export figures show that in the year prior to last September, the UK sold medicines worth over eleven billion pounds to the US. This value represented a significant portion of all goods exports in that span.
"This deal safeguards jobs, boosts investment and paves the way for the UK to become a global hub for medical research," the Business and Trade Secretary commented.
Key NHS Changes
The pact entails several specific pledges from the United Kingdom:
- Price Threshold Increase: The UK will lift the affordability limit at which it judges new treatments to be prohibitively costly by a quarter.
- Higher Drug Budget: There is a target to double overall NHS spending on treatments from 0.3% of the national economy to 0.6 percent over the coming ten years.
- Rebate Cap: The sum drug companies must pay back to the NHS to stay within budget will be capped at 15%. In the past, repayments topped twenty percent.
Broader Context
This agreement follows a long-running dispute between the pharmaceutical industry and the British authorities over spending levels and approval rates.
This friction were intensified by arguments that American patients were charged several times more for the equivalent treatments than patients in the Britain and the EU.
Over the last 18 months, several large drug company projects in the UK have been paused or scrapped, while major expansions have been pledged toward American operations.
One official acknowledged that the NHS must increase expenditure on treatments, noting that its spending on drugs had decreased as a proportion of its total funding over the previous ten-year period.
